The European Hematology Association 2023 Hybrid Congress (EHA2023)

In patients with previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL), treatment with subcutaneous (SC) rituximab is not inferior to intravenous (IV) rituximab in terms of serum trough levels, efficacy, and tolerability, as shown in a study presented at EHA 2023.

Obesity does not seem to have any significant impact on clinical outcomes, particularly survival, in patients with multiple myeloma (MM), according to a study presented at EHA 2023. However, obese MM patients aged <65 years tend to have a shorter overall survival (OS) than those with normal weight.

The anti-CD45 radioimmunoconjugate Iomab-B has been shown to safely deliver myeloablative doses of targeted radiation to the bone marrow of older patients with relapsed/refractory acute myeloid leukemia (R/R AML), improving the outcomes of subsequent allogeneic haematopoietic stem cell transplantation (HSCT).

In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).

In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.

The BMT CTN* 1506 (MORPHO) trial narrowly missed its primary outcome, but it did show that the potent oral FLT3 inhibitor gilteritinib conferred benefit for a subset of individuals with FLT3-ITD** acute myeloid leukaemia (AML).

In the ongoing pivotal phase III ALPHA trial, add-on danicopan, an investigational first-in-class oral inhibitor of Factor D, appears better than placebo in increasing haemoglobin levels and maintaining disease control in individuals with paroxysmal nocturnal haemoglobinuria (PNH) and clinically significant extravascular haemolysis (cs-EVH) who were already on C5 inhibitors (ravulizumab or eculizumab).

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.